These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 6707697)

  • 1. Immunobiology of primary intracranial tumors: IX. Phase I study of human lymphoblastoid interferon.
    Mahaley MS; Urso MB; Whaley RA; Staab EV; Williams TE; Guaspari A
    J Biol Response Mod; 1984; 3(1):19-25. PubMed ID: 6707697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic effect of human lymphoblastoid interferon (MOR-22) on malignant brain tumors--a phase II study].
    Hirakawa K
    Nihon Gan Chiryo Gakkai Shi; 1986 Jun; 21(5):1068-74. PubMed ID: 3760650
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I study of recombinant beta-interferon given by four-hour infusion.
    Grunberg SM; Kempf RA; Venturi CL; Mitchell MS
    Cancer Res; 1987 Feb; 47(4):1174-8. PubMed ID: 3802098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human alpha-lymphoblastoid interferon. A phase I study including pharmacokinetics and effects on hematologic stem cells (CFU-GMs).
    Sarna G; Figlin R; Bryson Y; Garratty E; Myers L; Le Fevre C; Mauritzon N; Cline M
    Am J Clin Oncol; 1985 Oct; 8(5):406-12. PubMed ID: 4061375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II evaluation of topotecan for pediatric central nervous system tumors.
    Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
    Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of high-dose human lymphoblastoid alpha interferon in patients with advanced renal carcinoma.
    Vugrin D; Hood L; Laszlo J
    J Biol Response Mod; 1986 Aug; 5(4):309-12. PubMed ID: 3734846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of human lymphoblastoid interferon in patients with multiple myeloma.
    Cox EB; Laszlo J; Krown S; Mintzer D; Sarna G
    J Biol Response Mod; 1988 Jun; 7(3):318-25. PubMed ID: 3392554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospectively randomized toxicity study of high-dose versus low-dose treatment strategies for lymphoblastoid interferon.
    Silver HK; Connors JM; Salinas FA
    Cancer Treat Rep; 1985; 69(7-8):743-50. PubMed ID: 4016785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of betaseron (beta ser17-interferon) as treatment of advanced malignant melanoma.
    Sarna GP; Figlin RA; Pertcheck M
    J Biol Response Mod; 1987 Aug; 6(4):375-8. PubMed ID: 3625229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha therapy of renal cancer.
    Neidhart JA; Gagen MM; Young D; Tuttle R; Melink TJ; Ziccarrelli A; Kisner D
    Cancer Res; 1984 Sep; 44(9):4140-3. PubMed ID: 6378379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
    Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
    Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II study of recombinant leukocyte A interferon (Ro 22-8181) in malignant brain tumors].
    Gan To Kagaku Ryoho; 1985 Apr; 12(4):913-20. PubMed ID: 3885862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.